KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Shares Outstanding (Weighted Average) (2019 - 2025)

GoodRx Holdings' Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $356.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 7.62% year-over-year to $356.3 million; the TTM value through Dec 2025 reached $356.3 million, down 7.62%, while the annual FY2025 figure was $356.3 million, 7.62% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $356.3 million at GoodRx Holdings, down from $360.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $413.4 million in Q2 2022 and bottomed at $356.3 million in Q4 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $400.0 million (2021), against an average of $393.6 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 49.25% in 2021 before it fell 7.65% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $410.0 million in 2021, then increased by 0.7% to $412.9 million in 2022, then fell by 0.62% to $410.3 million in 2023, then decreased by 5.99% to $385.7 million in 2024, then fell by 7.62% to $356.3 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Shares Outstanding (Weighted Average) are $356.3 million (Q4 2025), $360.7 million (Q3 2025), and $356.6 million (Q2 2025).